SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 32.02-0.8%2:17 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: aknahow who wrote (5222)1/1/1998 6:36:00 PM
From: Robert K.  Read Replies (2) of 17367
 
Also, I believe last report of expression liscencees was 11.
Investor fact sheet now lists(over 12). Thats not 11, not 11.5 not 12. Its over 12, so I guess thats at least 2 more.
Other confirmatory tidbits.

:
$6.750 (12/3/97) Common shares outstanding:
39.7 million (9/30/97) Market capitalization:
$267.98 million (12/3/97) Cash and investments:
$35.8 million (9/30/97) Ave. daily volume:
297,303 (11/97) Fiscal year end:
December 31st Headquarters:
Berkeley, CA Employees:
161 (11/30/97)

showed a particularly strong benefit in preventing pneumonia. XOMA has launched a 1650-patient Phase III pivotal trial testing Neuprex to prevent pulmonary complications (pneumonia or acute respiratory distress syndrome).

Study number three tested the product in patients who have undergone partial hepatectomy, a type of liver surgery, and are at risk of systemic infections and complications. An interim analysis of a 12-patient low-dose group in this Phase II double-blind study confirmed product safety. Furthermore, patients treated with Neuprex(tm) spent fewer days in intensive care and required less hospital support than those on placebo. Patient enrollment has been completed and an analysis of the data is underway.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News